McKesson (NYSE: MCK) to Buy Controlling Stake in Florida Cancer Specialists’ Unit for $2.5 Billion
On Monday, McKesson (NYSE: MCK), a drug distributor, said it would buy a controlling stake in community cancer center Florida […]
Healthcare
Novartis (NYSE: NVS) Receives Binding Offer from Siemens Healthineers for Molecular Imaging Business
On Saturday, Novartis (NYSE: NVS), a Swiss drugmaker, said it had received a binding offer from Germany’s Siemens Healthineers to
NHS Likely to Block Eli Lilly (NYSE: LLY) Alzheimer’s Treatment, The Telegraph Reports
Eli Lilly’s (NYSE: LLY) treatment for early Alzheimer’s is expected to be blocked for use by Britain’s National Health Service
NHS Likely to Block Eli Lilly (NYSE: LLY) Alzheimer’s Treatment, The Telegraph Reports Read More »
Analysis: Ozempic on Wall Street’s List for 2027 Medicare Drug Negotiations
NEW YORK – Now that the U.S. government has negotiated prices for some Medicare program drugs effective in 2026, Wall
Analysis: Ozempic on Wall Street’s List for 2027 Medicare Drug Negotiations Read More »
AstraZeneca Threatens UK Vaccine Exit Over Deadlocked State Aid Talks, FT Reports
AstraZeneca (NASDAQ: AZN) has warned it could relocate its vaccine manufacturing site from the UK to the United States as
AstraZeneca Threatens UK Vaccine Exit Over Deadlocked State Aid Talks, FT Reports Read More »
FDA Greenlights Updated COVID Vaccines to Combat New Variants Ahead of Fall Campaign
On Thursday, the U.S. Food and Drug Administration approved updated COVID-19 vaccines made by Pfizer (NYSE: PFE) and Moderna (NASDAQ:
FDA Greenlights Updated COVID Vaccines to Combat New Variants Ahead of Fall Campaign Read More »
UK State Health Service Declares New Alzheimer’s Drug Too Expensive for Widespread Use
Alzheimer’s patients in Britain’s state-run health service are unlikely to get access to Eisai and Biogen’s new Leqembi drug after
UK State Health Service Declares New Alzheimer’s Drug Too Expensive for Widespread Use Read More »
US Lawmakers Call for Increased Oversight of Clinical Trials Conducted in China
WASHINGTON – On Tuesday, a bipartisan group of lawmakers called on the Biden administration to ramp up scrutiny of U.S.
US Lawmakers Call for Increased Oversight of Clinical Trials Conducted in China Read More »
US FDA Approves Johnson & Johnson’s Combination Therapy for a Type of Lung Cancer
On Tuesday, the U.S. Food and Drug Administration approved Johnson & Johnson’s (NYSE: JNJ) chemotherapy-free combination treatment for a type
US FDA Approves Johnson & Johnson’s Combination Therapy for a Type of Lung Cancer Read More »
Healthcare
Mpox-Linked Stocks Extend Rally Into Second Week
Shares of some mpox vaccine and drug developers jumped sharply on Monday in premarket trading, putting them on track to
Mpox-Linked Stocks Extend Rally Into Second Week Read More »
Liquidia (NASDAQ: LQDA) Stock Tumbles as FDA Delays Traditional Approval for Lung Drug
On Monday, the U.S. Food and Drug Administration delayed traditional approval for Liquidia Corp’s (NASDAQ: LQDA) inhaled drug for types
Liquidia (NASDAQ: LQDA) Stock Tumbles as FDA Delays Traditional Approval for Lung Drug Read More »
Shares of Mpox Vaccine Developers Rally as Virus Spreads Beyond African Borders
Shares in companies making and developing products against mpox surged on Friday as the European Union’s public health body raised
Shares of Mpox Vaccine Developers Rally as Virus Spreads Beyond African Borders Read More »
Novo Nordisk (NYSE: NVO) to Build $220 Million Raw Materials Plant in Denmark
COPENHAGEN – Novo Nordisk’s (NYSE: NVO) Pharmatech unit will build a 1.5 billion Danish crown ($221 million) plant in Denmark
Novo Nordisk (NYSE: NVO) to Build $220 Million Raw Materials Plant in Denmark Read More »
GSK (NYSE: GSK) to Seek Dismissal of Florida Zantac Case Over Prostate Cancer Claims
On Friday, British drugmaker GSK (NYSE: GSK) said it would seek a dismissal of an upcoming Zantac case in Florida,
GSK (NYSE: GSK) to Seek Dismissal of Florida Zantac Case Over Prostate Cancer Claims Read More »
US Announces Prices in Medicare Drug Negotiations
The U.S. announced the final prices of its first-ever negotiation over prescription drugs on Thursday, with Merck’s (NYSE: MRK) diabetes
US Announces Prices in Medicare Drug Negotiations Read More »
US FDA Seeks Fresh Curbs on Sodium Levels in Packaged, Processed Foods
On Thursday, the U.S. Food and Drug Administration laid out fresh goals to cut sodium levels in packaged and processed
US FDA Seeks Fresh Curbs on Sodium Levels in Packaged, Processed Foods Read More »
Biden Administration Targets Top 10 Medicare Drugs for Price Negotiations
The Biden administration selected 10 prescription medicines for unprecedented price negotiations by the Medicare health program for older Americans that
Biden Administration Targets Top 10 Medicare Drugs for Price Negotiations Read More »
US To Save $6 Billion in First Year from Negotiated Medicare Drug Price Cuts
LARGO, Maryland/WASHINGTON – The United States has negotiated down the prices of 10 top-selling prescription drugs used by Medicare by
US To Save $6 Billion in First Year from Negotiated Medicare Drug Price Cuts Read More »
Doctors Face Hurdles in Securing Wegovy for Older Americans with Heart Disease
NEW YORK – Older Americans are having little success getting prescriptions for the weight-loss drug Wegovy covered by Medicare despite
Doctors Face Hurdles in Securing Wegovy for Older Americans with Heart Disease Read More »
AstraZeneca’s Imfinzi Receives FDA Priority Review for Small Cell Lung Cancer
On Thursday, AstraZeneca (NASDAQ: AZN) said the U.S. Food and Drug Administration (FDA) has granted its blockbuster cancer drug Imfinzi
AstraZeneca’s Imfinzi Receives FDA Priority Review for Small Cell Lung Cancer Read More »
Pfizer’s (NYSE: PFE) RSV Vaccine Proves Effective for Immuno-Compromised Adults in Study
On Monday, Pfizer (NYSE: PFE) said its respiratory syncytial virus (RSV) vaccine Abrysvo generated a strong immune response in a
Pfizer’s (NYSE: PFE) RSV Vaccine Proves Effective for Immuno-Compromised Adults in Study Read More »
Novavax (NASDAQ: NVAX) Slashes 2024 Revenue Guidance Again, To Cut European Presence
On Thursday, Novavax (NASDAQ: NVAX) trimmed its annual revenue forecast again and said it would pare back its presence in
Novavax (NASDAQ: NVAX) Slashes 2024 Revenue Guidance Again, To Cut European Presence Read More »
BioNTech (NASDAQ: BNTX) Q2 Losses Quadruple Amid Strategic Shift to Cancer Drugs
BERLIN – Losses at Germany’s BioNTech (NASDAQ: BNTX) quadrupled year-on-year in the second quarter, the company said on Monday, as
BioNTech (NASDAQ: BNTX) Q2 Losses Quadruple Amid Strategic Shift to Cancer Drugs Read More »
